Van der Wall, Sake J <br/><br/>
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.  [electronic resource] 

 -  Circulation  02 2019 
 - 748-756 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/CIRCULATIONAHA.118.036710  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Anticoagulants--adverse effects<br/>Dabigatran--adverse effects<br/>Drug Substitution<br/>Drug-Related Side Effects and Adverse Reactions--epidemiology<br/>Female<br/>Follow-Up Studies<br/>Gastrointestinal Hemorrhage--epidemiology<br/>Humans<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Risk Assessment<br/>United States--epidemiology<br/>Venous Thromboembolism--drug therapy<br/>Vitamin K--antagonists & inhibitors